A paper from UT College of Pharmacy researchers was awarded the 2021 Outstanding Paper of the Year from the American College of Clinical Pharmacy (ACCP) Ambulatory Care Practice Research Network. The paper investigates the availability of buprenorphine and naloxone in Texas to treat opioid use disorder.
Nathan Pope, Pharm.D., BCACP, FACA has been named The University of Texas at Austin College of Pharmacy’s new assistant dean of experiential education and will succeed Jennifer Ridings-Myhra, M.Ed., R.Ph., who plans to work with Dr. Pope through July and August to assist in the transition. The start date for this new role is effective July 1, 2021.
Combining mobile health technology, or mHealth, and community outreach to improve the health outcomes of people experiencing homelessness is the target of a new study led by Division of Health Outcomes Associate Professor Leticia Moczygemba, Pharm.D., Ph.D., thanks to a five-year research grant from the U.S. Department of Health and Human Services Agency for Healthcare Research and Quality.
Three researchers from the College of Pharmacy won an award from the Pharmaceutical Research and Manufacturers of America (PhRMA) Foundation. Leticia R. Moczygemba, Pharm.D., Ph.D., Carolyn M. Brown, Ph.D. and Michael Johnsrud, Ph.D., R.Ph. were awarded $5,000 from the PhRMA Foundation for their proposal to advance racial and ethnic representation in value assessments.
Two of the College of Pharmacy’s distinguished faculty were recently promoted due to their outstanding accomplishments in research, outreach and education. Dr. Kimberly Nixon of the Division of Pharmacology and Toxicology will assume the rank of professor and Dr. Lucas G. Hill of the Division of Pharmacy Practice will become a clinical associate professor.
It is with great sadness that we announce the passing of Edward (Ted) Mills, Ph.D., associate professor in the Division of Pharmacology and Toxicology and Bergen Brunswig Corporation Centennial Fellow.
Researchers in the lab of Dr. Hugh D.C. Smyth have released promising results of a new method to treat SARS-CoV-2, the coronavirus that causes COVID-19. The antiviral niclosamide, when incorporated with human lysozyme as a carrier molecule, shows potential as an effective COVID-19 treatment when delivered directly to the airways.
Professor Rueben Gonzales of the Department of Pharmacology and Toxicology was named a fellow of the American Association for the Advancement of Science (AAAS) for distinguished contributions to the field of alcohol research.